Blog
Darden's Portfolio Strength: Are All Segments Finally Firing Together?
Darden Restaurants DRI is increasingly demonstrating that its multi-brand portfolio is operating in sync, a notable shift from the uneven performance seen in prior periods. In the third quarter of
Pre-markets Lower on Concerns About Iran
Thursday, April 2nd, 2026Pre-market futures are off early morning lows, but still fairly deep in the red at this hour. Following a prime-time speech from President Trump yesterday, where investors
Recurring Subscription Revenues & Buyouts Aid Verisk Amid High Debt
Verisk VRSK is benefiting from its recurring subscription-based revenue model. Rising direct premium growth and a robust liquidity position are driving VRSK’s sustainable growth. Recent acquisitions
Can Group Ordering and Catering Support Sales Recovery for Chipotle?
Chipotle Mexican Grill, Inc. CMG is focusing on new demand channels to revive sales momentum. Group ordering and catering are emerging as key opportunities as the company looks to drive higher
NIKE's Gross Margin Drag & Tariff Costs Loom: Can It Protect Profits?
Gross margin pressure remains a central concern for NIKE, Inc. NKE as tariff-related costs and ongoing marketplace clean-up efforts weigh on near-term profitability. The company continues to
3 Growth Stocks From the P&C Insurance Space to Enhance Your Portfolio
The Zacks Property and Casualty Insurance industry is placed within the top 16% of the 243 Zacks industries. It currently carries Zack Industry Rank #38. The insurers remain well-poised for growth
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study
Ocugen OCGN announced that enrollment and dosing have been completed in the phase II/III GARDian3 pivotal confirmatory study evaluating its pipeline candidate, OCU410ST, for the treatment of
SpaceX IPO Set to Be a Catalyst for 2026 IPO Boom: ETFs to Gain
Elon Musk’s SpaceX has taken the next step toward a landmark IPO by confidentially filing with the SEC, setting the stage for a potentially record-setting public offering, as reported by Bloomberg
Shell Reportedly Targets New Venezuelan Gas Areas to Boost LNG Supply
Shell plc SHEL is reportedly advancing negotiations with Venezuela’s government to expand its presence in the country’s most promising offshore natural gas fields. The London-based integrated oil
Is Procter & Gamble's Supply Chain 3.0 a Catalyst for Margin Growth?
The Procter & Gamble Company’s PG next-generation Supply Chain 3.0 initiative is emerging as a critical pillar in the company’s long-term productivity and margin expansion strategy. As consumer
Waste Services Expertise Aids WM Amid High Debt & Low Liquidity
WM WM is benefiting from its robust infrastructure and extensive asset network in the waste removal services industry. A stable industry that provides essential services is driving WM’s sustainable
JNJ Q1 MedTech Preview: Key Drivers and China Headwinds to Watch
Johnson & Johnson's JNJ MedTech division, which spans orthopedics, surgery, cardiovascular and vision care, contributes roughly 36% to the company’s total revenues.
J&J is repositioning its MedTech
3 Reasons to Hold Microsoft Stock Despite 28.6% Drop in 6 Months
Microsoft MSFT has had a rough run in recent months, with its stock shedding 28.6% in the past six-month period, underperforming the Zacks Computer and Technology sector's decline of 7.9% as the
Earnings Preview: Neogen (NEOG) Q3 Earnings Expected to Decline
The market expects Neogen (NEOG) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended February 2026. This widely-known consensus outlook is
Earnings Preview: Simply Good Foods (SMPL) Q2 Earnings Expected to Decline
Simply Good Foods (SMPL) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended February 2026. This widely-known consensus
Analysts Estimate Byrna Technologies Inc. (BYRN) to Report a Decline in Earnings: What to Look Out for
Wall Street expects a year-over-year decline in earnings on higher revenues when Byrna Technologies Inc. (BYRN) reports results for the quarter ended February 2026. While this widely-known
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
ROKU Slumps 12% YTD: Here's Why It Is Time to Buy the Stock
Roku Inc. ROKU shares have experienced significant volatility and a notable 12% year-to-date (YTD) decline, underperforming the broader Zacks Consumer Discretionary sector and the Zacks Broadcast
Best Momentum Stocks to Buy for April 2nd
Here is a stock with buy rank and strong momentum characteristics for investors to consider today, April 2:
Flowco Holdings Inc. FLOC: This provider of production optimization, artificial lift and
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?
Shares of NeuroPace, Inc. (NPCE) have gained 0.9% over the past four weeks to close the last trading session at $14.07, but there could still be a solid upside left in the stock if short-term price
Wall Street Analysts Predict a 201.49% Upside in Aura Biosciences (AURA): Here's What You Should Know
Aura Biosciences, Inc. (AURA) closed the last trading session at $6.7, gaining 8.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
Wall Street Analysts Predict a 25.11% Upside in Marex Group PLC (MRX): Here's What You Should Know
Marex Group PLC (MRX) closed the last trading session at $43.05, gaining 7.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts Predict a 75.44% Upside in nCino (NCNO): Here's What You Should Know
nCino (NCNO) closed the last trading session at $16.57, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street
Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a Bet
vTv Therapeutics (VTVT) closed the last trading session at $40.53, gaining 12.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know
Shares of Vor Biopharma Inc. (VOR) have gained 15.6% over the past four weeks to close the last trading session at $17.39, but there could still be a solid upside left in the stock if short-term


